Učitavanje...
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer
PURPOSE: In a recent Phase II clinical trial, low dose (100 mg/kg) gemcitabine showed promise as a radiosensitiser in bladder cancer but underlying mechanisms lack elucidation. Here we investigated the mechanism of radiosensitisation by low-dose gemcitabine in bladder cancer cell lines. EXPERIMENTAL...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4216732/ https://ncbi.nlm.nih.gov/pubmed/25224279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0542 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|